Genetic Testing for Patients with Autism Spectrum Disorders


2024 SFASA-Stanford Bay Area Adult Autism/DD Conference

Jon Bernstein MD, PhD Stanford School of Medicine




Autism and Genetics

Autism is defined by observable aspects of learning and behavior




Genetic Testing for Autism Spectrum Disorders


- Autism results from a combination of genetic and environmental factors
 - The relative contributions can vary substantially between individuals
 - Genetic causes or contributors to autism risk can be of varying strength
 - One large genetic factor can largely explain some cases of autism
 - Weaker genetic factors when combined with each other explain many cases of autism
- At present genetic testing is most effective in identifying large/strong genetic factors related to autism



The Autism Spectrum



An emerging map of autism spectrum disorders



Autism care without a genetic diagnosis

- Management may include
 - Behavioral therapy
 - Psychiatric care
 - Educational planning
 - Financial and legal planning
 - Vocational training
 - Identification of residential living options
 - Accessing resources
- Prognosis
 - Dependent on severity and response to treatment
- Genetic counseling
 - Familial recurrence risk
 - The risk to the male sibling of an affected male is commonly estimated as 7-14% for classic autism. The risk of an autism spectrum disorder is higher.
 - If there are two affected siblings in a family the risk to the next child may be approximately 35%.
 - Option to participate in patient and family support groups



Autism care with a genetic diagnosis

- Management may include
 - Behavioral therapy
 - Psychiatric care
 - Educational planning
 - Financial and legal planning
 - Vocational training
 - Identification of residential living options
 - Accessing resources
 - Monitoring for specific symptoms
 - Screening for medical and developmental issues
 - Eligibility for clinical trials
- Prognosis
 - Dependent on the specific genetic cause as well as other factors
- Genetic counseling
 - Familial recurrence risk
 - Can be estimated precisely, sometimes <1%, less commonly 25% or up to 50%
 - Option to participate in patient and family support groups



Motivations for Genetic Testing

- Guide management
- Inform prognosis
- Inform recurrence risk counseling



Yield of testing for autism with intellectual disability

- DNA Microarray testing for DNA deletions or duplications
 - Up to approximately 10%
- Whole genome sequencing
 - With current methods, up to approximately 30% in the presence of intellectual disability
 - Fragile X syndrome, specialized testing method, approximately 1%

• Yield in high functioning autism is significantly lower



Findings suggestive of an identifiable genetic cause of autism

- Family history suggesting X-linked or other monogenic inheritance pattern
- Intellectual disability
- Microcephaly
- Macrocephaly
- Overgrowth
- Atypical physical features
- Marked developmental regression
- Vascular or pigmented birthmarks
- Multi-system disease



Utility of Genetic Testing

- Guiding care
 - Increasing confidence in current care
- Predicting the future
 - Often less informative in older children and adults
- Family planning
- Reducing uncertainty
- Relief from feelings of responsibility



The process of genetic testing

- 1. Pre-test counseling and consent for testing
- 2. Insurance benefits verification
- 3. Sample collection
 - Blood or saliva samples most commonly used
- 4. Testing
- 5. Post-test counseling and disclosure of results
 - Screening recommendations
 - Changes in management
 - Updated recurrence risk counseling



Insurance coverage for genetic testing

- Varies between plans and payors
 - May not cover any testing
 - May only cover certain types of tests
 - May only cover if ordered in a specific sequence or by a particular type of specialist
- Options if not covered or incompletely covered
 - Testing companies that limit out of pocket expenses
 - Can consider research testing
- Recent trends are towards lower costs overall and increased coverage of testing by health plans



Pre-test counseling

- Genetic testing may identify
 - A positive result explaining a patient's symptoms
 - A negative result
 - A result of unclear significance that potentially may be clarified by testing additional family members
 - A positive result related to a disease unrelated to the indication for testing
 - Some types of genetic testing can reveal that a family's structure is different than currently believed



Secondary or incidental findings

- Some types of testing can identify genetic changes that are not associated with the reason testing was performed
 - Risk for a specific disease
 - Cancer, cardiomyopathy, arrhythmia



Methods of Genetic Testing

- Cytogenetic testing
 - Chromosome analysis
 - DNA Microarray
- Molecular genetic testing
 - Assessing for trinucleotide repeat expansions (Fragile X)
 - DNA sequencing
 - Gene Panels
 - Whole exome/genome sequencing





How long does testing take

- Usually, 2-4 weeks for routine testing such as fragile X or DNA microarray studies
- Sequencing based tests can be expedited, but are routinely completed in 2-8 weeks



 A 19-year-old female with a history of high functioning autism has developed unexplained agitation, distress and is no longer able to perform several tasks she was previously able to. DNA microarray testing is performed.







Source: MedlinePlus, National Library of Medicine.

- The results of testing identify the absence of 1 copy of the *SHANK3* gene on chromosome 22. This finding is consistent with a diagnosis of Phelan-McDermid syndrome.
 - Management
 - Screening evidence of seizures
 - Ultrasound of kidneys (less likely in this patient)
 - Cardiovascular evaluation
 - Screening for lymphedema (less likely in this patient)
 - Consultation with expert clinicians regarding psychiatric symptoms in Phelan-McDermid syndrome
 - Eligibility for clinical trials
 - Prognosis
 - Increased risk of seizures, lymphedema and psychiatric conditions
 - Genetic counseling
 - Option to test parents for the gene deletion.
 - Recurrence risk often low for siblings of an affected individual, but possibly as high as 50%
 - Option to be involved with patient and family groups



 28-year-old female with a history of autism, intellectual disability and a large head circumference has previously had fragile X testing and a DNA microarray. Additional genetic testing is performed by sequencing.



- Genetic testing identified a disease-causing change in the PTEN gene.
 - Management
 - Cancer screening
 - Eligibility for clinical trials
 - Prognosis
 - Increased risk of cancer in patient and potentially in other family members if the genetic change were inherited
 - Genetic counseling
 - Option to test parents for the gene mutation.
 - Option to be involved with patient and family groups.
 - Option to pursue clinical trials



- 2-year-old typically developing girl with a family history of high functioning autism in her older brother. DNA microarray identifies a deletion on the long arm of chromosome 15 at 15q13.3.
- The deletion is also present in her brother, her mother and her maternal grandfather



- Genetic testing identified a deletion on chromosome 15 at 15q13.3
- Management
 - Consider echocardiogram
 - Consider renal ultrasound
 - Eye exam
 - Eligibility for clinical trials
 - Prognosis
 - Increased risk for neurodevelopmental symptoms
 - Genetic counseling
 - Individuals with the deletion have a 50% risk of passing it on to each of any offspring, however, the associated risk of symptoms is less than this





- For patients with autism and intellectual disability there is an appreciable likelihood that a single genetic change may explain the diagnosis
 - Commonly utilized testing includes Whole exome sequencing, DNA microarray and fragile X testing
- Genetic diagnoses can have implications for management, prognosis and counseling and in some cases for the health of other family members
- The utility of genetic testing may vary from patient to patient and family to family
- The utility cannot be fully defined until testing results are available

